Iovance Biotherapeutics, Inc. IOVA Balance Sheet Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $196.51M+14.5% | $163.08M+41.0% | $158.13M-7.3% | $132.47M-43.7% | $171.67M+27.9% | ||
| $116.94M-37.8% | $133.9M-35.7% | $142.67M-38.8% | $168.71M-8.2% | $188.05M-15.3% | ||
| $81.76M+15.3% | $82.45M+18.9% | $66.76M+19.7% | $59.94M+89.7% | $70.94M+30,215% | ||
| $58.38M-10.9% | $51.68M+0.3% | $51.71M+34.0% | $49.83M+78.9% | $65.55M+272% | ||
| $466.5M-9.0% | $442.69M-3.1% | $429.09M-13.9% | $422.5M-12.4% | $512.65M+33.0% | ||
| $131.39M+17.8% | $131.11M+20.2% | $126.65M+12.6% | $122.47M+10.4% | $111.58M-0.2% | ||
| $269.1M-5.7% | $279.32M-1.1% | $285.21M-7.0% | $296.25M+0.3% | $285.36M-3.0% | ||
| $925.67M-4.2% | $913.17M+0.3% | $904.95M-8.7% | $907.44M-5.9% | $966.74M+11.1% | ||
| $37.45M+31.5% | $22.16M-19.4% | $31.24M-1.4% | $32M+56.8% | $28.49M+10.9% | ||
| $129.42M+5.5% | $138.36M+13.1% | $125.79M+6.5% | $129.16M+37.9% | $122.69M+47.4% | ||
| $74.49M-2.2% | $76.23M-1.9% | $76.88M-22.8% | $79.79M-21.9% | $76.18M-28.5% | ||
| $203.91M+2.5% | $214.59M+7.3% | $202.66M-6.9% | $208.95M+6.7% | $198.88M+4.8% | ||
| $18K+28.6% | $17K+30.8% | $16K-100.0% | $14K-100.0% | $14K+16.7% | ||
| -$2.85B-14.2% | -$2.78B-16.4% | -$2.7B-17.2% | -$2.61B-17.5% | -$2.5B-17.7% | ||
| $721.75M-6.0% | $698.58M-1.7% | $702.29M-9.2% | $698.49M-9.1% | $767.87M+12.9% | ||
| $925.67M-4.2% | $913.17M+0.3% | $904.95M-8.7% | $907.44M-5.9% | $966.74M+11.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Iovance Biotherapeutics, Inc.'s total assets?
- Iovance Biotherapeutics, Inc. (IOVA) holds $925.7M in total assets, down 4.3% year over year.
- How much debt does Iovance Biotherapeutics, Inc. have?
- Iovance Biotherapeutics, Inc. carries $46.8M in total debt against $721.8M of shareholders' equity, a debt-to-equity ratio of 0.06.
- How much cash does Iovance Biotherapeutics, Inc. have?
- Iovance Biotherapeutics, Inc. holds $196.5M in cash and equivalents.
- Can Iovance Biotherapeutics, Inc. cover its short-term obligations?
- Its current ratio is 3.60 — current assets exceed current liabilities.
- Where does Iovance Biotherapeutics, Inc.'s balance sheet data come from?
- Every line is extracted from Iovance Biotherapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
